Skip to main content
Yabao Pharmaceutical Group Co.,Ltd logo

Yabao Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 600351 ISIN · CNE000001CM5 LEI · 65560071PKRS4UHMVU53 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,360 across all filing types
Latest filing 2024-08-16 Investor Presentation
Country CN China
Listing Shanghai Stock Exchange 600351

About Yabao Pharmaceutical Group Co.,Ltd

http://www.yabao.com.cn

Yabao Pharmaceutical Group Co.,Ltd. focuses on the research, development, manufacturing, and commercialization of pharmaceutical products. The company maintains a specialized portfolio across therapeutic areas including pediatrics, cardiovascular health, and endocrinology. Key offerings include traditional Chinese medicines, chemical drugs, and innovative transdermal patches, such as the Dinggui Erqi Patch. The organization operates integrated production bases and research facilities dedicated to advancing drug delivery systems and biotechnological applications. Its business model emphasizes the modernization of traditional therapies alongside the development of conventional pharmaceuticals to address diverse clinical needs.

Recent filings

Filing Released Lang Actions
亚宝药业集团股份有限公司关于召开2024年半年度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling and details of a 2024 half-year performance explanation meeting (业绩说明会) for investors. It references the company's 2024 half-year report already published on August 15, 2024, and invites investors to participate in an interactive online session to discuss the half-year results. The document does not contain actual financial statements or detailed financial analysis but serves as a notice for the upcoming investor presentation event. According to the classification rules, such announcements about meetings explaining financial results are best classified as Investor Presentation (IP) rather than the report itself (which would be an Interim/Quarterly Report IR). The document length is short (1414 characters), and it is clearly an announcement of a meeting, not the report itself or a transcript. Therefore, the correct classification is Investor Presentation (IP).
2024-08-16 Chinese
亚宝药业集团股份有限公司2024年半年度报告
Interim / Quarterly Report Classification · 95% confidence The document is titled '2024 年半年度报告' which translates to '2024 Semi-Annual Report'. It covers a reporting period from January 1, 2024 to June 30, 2024, indicating it is a report for a period shorter than a full fiscal year. The content includes detailed financial data, management discussion and analysis, company overview, industry analysis, product information, and operational details. The length is substantial (15,000 characters), and it contains actual financial statements and substantive financial analysis. This matches the definition of an Interim / Quarterly Report (IR). It is not an announcement or a brief summary, nor is it a full annual report (10-K). Therefore, the correct classification is IR with high confidence. H1 2024
2024-08-14 Chinese
亚宝药业集团股份有限公司第九届董事会第六次会议决议公告
Board/Management Information Classification · 95% confidence The document is a board meeting resolution announcement from 亚宝药业集团股份有限公司, detailing decisions made at the ninth board's sixth meeting. It includes approval of the 2024 half-year report, a share repurchase proposal to be submitted to a shareholders meeting, and the convening of an extraordinary shareholders meeting. The document is short (661 characters) and does not contain the actual half-year financial report but references it and provides a link to the Shanghai Stock Exchange website for details. It also announces the board's resolutions rather than the full report or detailed financial data. Therefore, it is not an Interim/Quarterly Report (IR) itself but an announcement of board decisions and related matters. The best fitting category is Board/Management Information (MANG) because it reports on board meeting resolutions and management decisions. Confidence is high due to clear content and format.
2024-08-14 Chinese
亚宝药业集团股份有限公司关于以集中竞价交易方式回购股份方案的公告
Transaction in Own Shares Classification · 100% confidence The document is a detailed announcement regarding a company's plan to repurchase its own shares through a centralized bidding transaction. It includes specifics such as the purpose of the repurchase (to reduce registered capital), the total amount of funds allocated, the repurchase price limits, the timeline, and the impact on the company's capital structure. The document also discusses the approval process, risks, and authorizations related to the share repurchase. There is no indication that this is a financial report, earnings release, or regulatory certification. Instead, it clearly describes a share buyback plan, which fits the category of a Transaction in Own Shares (POS). The document length is about 4,312 characters, which is sufficient to be the actual announcement rather than a brief notice or report publication announcement.
2024-08-14 Chinese
亚宝药业集团股份有限公司2024年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2024 半年度报告摘要' which translates to '2024 Half-Year Report Summary'. It contains detailed financial data for the half-year period, including total assets, net profit, revenue, and shareholder information. The document explicitly states it is a summary of the half-year report and advises investors to read the full half-year report for comprehensive information. The presence of substantive financial data and analysis for a period shorter than a full fiscal year aligns with the definition of an Interim / Quarterly Report (IR). The document length is 2512 characters, which is relatively short but contains actual financial data, not just an announcement or certification. Therefore, it should be classified as an Interim / Quarterly Report (IR). H1 2024
2024-08-14 Chinese
亚宝药业集团股份有限公司关于召开2024年第一次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice about convening the 2024 first extraordinary general meeting of shareholders (临时股东大会) for a company, detailing the meeting date, voting methods, agenda items, and procedural instructions. It includes information about the shareholder meeting logistics and proxy voting but does not contain any financial statements or results. The document is an announcement of a shareholder meeting rather than a report or results announcement. The main agenda includes a share repurchase plan, but this is part of the meeting agenda, not a financing update or capital change announcement by itself. Given the content and length (3263 characters), it fits best as a Proxy Solicitation & Information Statement (PSI), which covers materials sent to shareholders to provide information and request votes for meetings.
2024-08-14 Chinese

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.